A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC) · G12D Mutated KRAS

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • START- Los Angeles, Los Angeles, California, United States

    Contact: Study coordinator (Hope Team) · hopeteam@startresearch.com
    Contact: Principal Investigator (Navid Hafez, MD)
  • Valkyrie Clinical Trials, Los Angeles, California, United States

    Contact: Study coordinator (Trenis Palmer) · trenis.palmer@vctcare.com · 4245351874
    Contact: Principal Investigator (David Berz, MD)
  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Brianna Holder) · Brianna.Holder@moffitt.org
    Contact: Principal Investigator (Dae-Won Kim, MD)
  • Johns Hopkins University, Baltimore, Maryland, United States

    Contact: Study coordinator (Colleen Apostol) · apostco@jhmi.edu
    Contact: Principal Investigator (Mari Nakazawa, MD)
  • START Midwest, Grand Rapids, Michigan, United States

    Contact: Study coordinator (Hope Team) · hopeteam@startresearch.com
    Contact: Principal Investigator (Sreenivasa Chandana, MD)
  • Washington University, St Louis, Missouri, United States

    Contact: Study coordinator (Olive Pressey) · olive@wustl.edu
    Contact: Principal Investigator (Kian-Huat Lim, MD)
  • START New Jersey, East Brunswick, New Jersey, United States

    Contact: Study coordinator (Hope Team) · hopeteam@startresearch.com
    Contact: Principal Investigator (Bruno Fang, MD)
  • University of North Carolina, Chapel Hill, North Carolina, United States

    Contact: Study coordinator (Catherine Griffin) · catherine_griffin@med.unc.edu
    Contact: Principal Investigator (Ashwin Somasundaram, MD)
  • Sarah Cannon Research Institute, Nashville, Tennessee, United States

    Contact: Study coordinator (Karlie Williams) · Karlie.Williams@scri.com · 6153297274
    Contact: Principal Investigator (Meredith Pelster, MD)
  • START Dallas, Fort Worth, Texas, United States

    Contact: Study coordinator (Hope Team) · hopeteam@startresearch.com
    Contact: Principal Investigator (Salwan Almutar, MD)
  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Michelle Escano-Caballero) · MEscano@mdanderson.org · 7137941776
    Contact: Principal Investigator (Shubham Pant, MD)
  • START- San Antonio, San Antonio, Texas, United States

    Contact: Study coordinator (Hope Team) · hopeteam@startresearch.com
    Contact: Principal Investigator (Drew Rasco, MD)
  • START- Mountain Region, West Valley City, Utah, United States

    Contact: Study coordinator (Julianna Daley) · Julianna.daley@startresearch.com
    Contact: Principal Investigator (William McKean, MD)
  • UVA Health, Charlottesville, Virginia, United States

    Contact: Study coordinator (Clinical Trials Navigator) · UVACANCERTRIALS@uvahealth.org · 4349820539
    Contact: Principal Investigator (Matthew Reilley, MD)
  • Virginia Cancer Specialists, Fairfax, Virginia, United States

    Contact: Study coordinator (Michelle Blair) · TNS8MW@uvahealth.org · 4342437264
    Contact: Principal Investigator (Alexander Spira, MD)
  • UW Health, Madison, Wisconsin, United States

    Contact: Study coordinator (Cancer Connect) · cancerconnect@uwhealth.org · 8006228922
    Contact: Principal Investigator (Noelle LoConte, MD)
  • ICON Kurralta Park, Kurralta Park, South Australia, Australia

    Contact: Study coordinator (Sarah Gartland) · Sarah.gartland@icon.team · 08 84740420
    Contact: Principal Investigator (Carolyn Bampton, MD)
  • ICON Cancer Centre, South Brisbane, Australia

    Contact: Study coordinator (Apryl Chelin) · Apryl.chelin@icon.team
    Contact: Principal Investigator (Jermaine Coward, MD)